-
pulmoseek™ plusdiagnosis of benign and malignant pulmonary nodules
-
urifind®urothelial carcinoma non-invasive methylation detection product
-
uriinstanttmurothelial cancer early screening product
-
pulmopathmethylation test for auxiliary diagnosis of early lung cancer, improving the overall clinical diagnosis rate
-
pulmoinsightai-aided analysis system based on ct images of pulmonary nodules
research and development
anchorviola® library preparation technology for somatic mutation detection
anchoriris® library preparation technology for dna methylation profiling
anchormonarch® dna methylation analysis software
thunder project
angel-2 program
multicenter clinical study on non-invasive diagnosis of bladder cancer by dna methylation
multiple research findings were published in journal of clinical investigation, an internationally renowned academic journal, and npj breast cancer, a sub-journal of nature (cas q1), etc.
![/public/uploads/uploadfile2/images/20240204/[fuben][fuben][fuben][fuben][fuben]shengji(1).png](/uploads/image/puui20240204/[fuben][fuben][fuben][fuben][fuben]shengji(1).png)
about us
anchordx, established in 2015, is a pioneer of applying ctdna high-throughput methylation sequencing technology in early detection of tumors in china. focusing on two major lines: "a tube of blood" and "a tube of urine", anchordx has developed products covering more than 70% of high-incidence cancers, such as lung cancer, breast cancer, digestive system cancer and urinary system cancer, throughout the process of early cancer screening, early diagnosis, recurrence monitoring and companion diagnostics.
in technology development
of high-incidence cancers
people benefited